According to China's customs statistics, the import and export of medical and health products in China amounted to 116.676 billion U.S. dollars, up 12.64 percent over the previous year, of which exports reached 60.799 billion U.S. dollars, reversing the decline of last year, up 9.44 percent, reaching the highest level in nearly five years ; Imports 55,877,000,000 US dollars, an increase of 16.34%; foreign trade surplus 4.92 billion US dollars, down 34.60%.
Looking at the whole year of 2017, on the one hand, the pharmaceutical trade in our country experienced a marked increase in the number of trade frictions, the competition in the new round of international industry was more fierce, and the affordability of some emerging economies was adversely affected. On the other hand, the overall global economy showed a recovery The demand for medical and pharmaceutical products in the international market has stabilized and picked up. The pharmaceutical export structure in China has been further optimized, the pace of internationalization of enterprises has been accelerated, new momentum of development has been formed, and the overall development of pharmaceutical trade has been on the rise.
'Exit' 'as the main tune
Overall, the demand in the international market in 2017 has risen. The reform on the supply side of our country has seen initial success. The export volume of medical products has increased at a reduced price, and the volume of exports has steadily risen.
Chinese medicine pick up: the performance of the key market differentiation
In 2017, the export value of Chinese medicine was 3,640 million U.S. dollars, up 2.07% over the same period of last year. Key markets showed a widening gap. The markets of ASEAN, the United States and the EU maintained their growth with increases of 17.19%, 8.94% and 5.34% respectively. Exports to Japan slightly increased by 0.81% %; While exports to China, Hong Kong and South Korea decreased by 12.54% and 9.8% respectively, which were the main reasons for the slowdown in the growth of exports of Chinese medicine.
According to the export classification of Chinese medicine, the plant extract market is active with an export volume of 2.01 billion U.S. dollars, an increase of 4.33% over the same period of last year. The export of proprietary Chinese medicines was 250 million U.S. dollars, up 11.03% over the same period of last year. The exports of Chinese herbal medicines and Pieces continued to decline, down 2.23% Market downturn is the main reason for the negative growth of Chinese herbal medicines and Pieces.
Western medicine rose sharply: to achieve double-digit growth
In 2017, the export of western medicine products in China reached 35.456 billion U.S. dollars, up 12.62%.
Among them, the export of APIs 29.117 billion US dollars, an increase of 13.71%. For the United States, the European Union, India and other major markets increased by 23.84%, 9.79%, 13.52%. Raw materials pharmaceutical companies continue to rise in environmental costs, prompting the supply side contraction, backward production capacity gradually Exit, the competitive landscape of high-quality enterprises ushered in a continuous improvement, the international market share and bargaining power are gradually increasing, the concentration of exporters and the increase of export prices are two main features. In 2017, the average export price of 25 bulk raw materials increased 10.45 %, Is the main reason for stimulating the export growth of bulk drugs.
The export of preparations reached 34.56 billion U.S. dollars, up 8.32% over the same period of 2007. There are two specific characteristics: First, the growth points in the international market are changing. For the EU and North America, the market for norms has been growing strongly, of which the export to the EU is 670 million U.S. dollars, a substantial increase of 53.51% Africa's exports increased by 11.2%, while the average performance of Asian markets declined by 7.83% .Second, the research and development of innovative pharmaceutical companies gradually became the major exporters of pharmaceutical exporters .Huahai Pharmaceutical, Hengrui Medicine, Guilin Pharmaceutical and other pharmaceutical companies in the export volume In spite of the rapid growth, the number of ANDAs granted by the U.S. continued to grow, opening the way for subsequent growth.
The export of biochemical drugs was 2.883 billion U.S. dollars, up 7.36% over the same period of 2010. The main factor was that the export price of heparin sodium, the largest exporter of biochemical drugs, soared 24.11% and the export value reached 788 million U.S. dollars, up 29.33% .In addition, with the increase of domestic blood products supply, Exports surged 508.3%.
Medical equipment steady growth: the future fancy high-end breakthrough
In 2017, the export amount of medical devices was 21,730 million U.S. dollars, up 5.84% from the same period of last year. The medical dressings, disposable consumables, diagnosis and treatment equipment, health rehabilitation equipment and dental equipment all achieved a steady growth of 2.97%, 9.53% and 4.11% , 6.29%, 17.00%. The United States, European Union, Japan, India, Latin America and other markets to expand market share, exports of Brazilian equipment substantial growth of 32.72%, while the slow growth of the ASEAN, Africa market.
Further analysis of the export data shows that the current low and medium-end equipment in China has a high degree of saturation in the international market and exports of equipment have entered a period of slow growth with limited growth in the major markets. The bright spot in the market is only reflected in the populous countries such as India and Brazil. The future growth depends on High-end equipment products to the mainstream market breakthrough.
'Import' to maintain double-digit growth
In 2017, domestic demand remained at a high level with rapid growth of imports, and the annual import value of China's pharmaceutical products was 55.877 billion U.S. dollars, up 16.34% over the same period of last year.
Among them, the import of western medicine, which ranks first among the imported pharmaceutical products in China, was 17.157 billion U.S. dollars, up by 21.66%. The import and export of hospital diagnostic and treatment equipment was 14.631 billion U.S. dollars, up 9.60% over the same period of last year.
According to incomplete statistics, about 20 innovative pharmaceuticals approved by foreign-funded enterprises in China were approved for listing in China in about 35% of cancer drugs in 2016 as the priority review system officially landed in China.
At present, the capacity of Chinese pharmaceutical enterprises in international registration certification, research and development, international marketing, and global resource portfolio continues to improve. The product mix and market structure of pharmaceutical exports are undergoing profound changes. The overall international trade environment for pharmaceuticals it is good.
The favorable factors are: the recovery in demand in the major markets such as the United States, the European Union and India and their expected steady growth; the export of products such as preparations and medical devices to the markets in Europe and the United States accelerated significantly; the rigid demand for bulk APIs and medical devices in the global pharmaceutical market did not Changes, exports and prices are gradually picking up as the global economy recovers.
However, uncertainties such as South America, Africa and other markets still exist and the impact of pharmaceutical trade friction can not be ignored.
With the implementation of the 13th Five-Year Plan for API Pharmaceutical Industry, China's pharmaceutical industry will be more conducive to export structure by more orderly, higher technological content, environmental protection, resource conservation, higher added value and downstream extension Of the continuous optimization and upgrading.It is expected that in 2018 the fundamentals of the steady development of pharmaceutical foreign trade will continue to be maintained.
Click on the picture below to register the show!
